AcquisitionOther
ANTARES PHARMA, INC. acquired Antares Pharma to Create a Specialty Product
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
ANTARES PHARMA, INC. -> Antares Pharma to Create a Specialty Product · $960 million
The transaction is expected to be immediately accretive to Halozyme’s 2022 revenue and non-GAAP earnings and to accelerate top- and bottom-line growth through 2027, with multiple growth drivers beyond 2027.
Open source record (SEC) ↗